Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Pharmacokinetics and Pharmacodynamics

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10928-007-9080-2PMID 18058203
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modeling the Exposure‐Response Relationship of Etanercept in the Treatment of Patients With Chronic Moderate to Severe Plaque Psoriasis

  2007cited by this paper
• Collapsing Mechanistic Models: An Application to Dose Selection for Proof of Concept of a Selective Irreversible Antagonist

  2005cited by this paper
• Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor

  2004cited by this paper
• Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis

  2003cited by this paper
• A Two-Part Mixture Model for Longitudinal Adverse Event Severity Data

  2003cited by this paper
• Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

  2003cited by this paper
• Pathogenesis of rheumatoid arthritis.

  1997cited by this paper
• Random effects probit and logistic regression models for three-level data.

  1997cited by this paper
• Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data from Analgesic Trials

  1997cited by this paper
• Characterization of four basic models of indirect pharmacodynamic responses

  1996cited by this paper
• [ACR preliminary definition, of improvement in rheumatoid arthritis].

  1996cited by this paper
• Signaling by IL‐2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency

  1996cited by this paper
• American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

  1995cited by this paper
• Comparison of four basic models of indirect pharmacodynamic responses

  1993cited by this paper
• Regression Models for Ordinal Data

  1980cited by this paper
• Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

  1980cited by this paper
• Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine

  1979cited by this paper
• Handbook of Mathematical Functions.

  1966cited by this paper

• Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients

  2024cites this paper
• Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm

  2024cites this paper
• Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework

  2024cites this paper
• A framework for precision “dosing” of mental healthcare services: algorithm development and clinical pilot

  2023cites this paper
• Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis

  2023cites this paper
• Role of Disease Progression Models in Drug Development

  2022cites this paper
• Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy

  2021cites this paper
• Improving categorical endpoint longitudinal exposure–response modeling through the joint modeling with a related endpoint

  2021cites this paper
• Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes

  2020cites this paper
• Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments

  2020cites this paper
• Application of Beta-Distribution and Combined Uniform and Binomial Methods in Longitudinal Modeling of Bounded Outcome Score Data

  2020cites this paper
• Facilitating Longitudinal Exposure-Response Modeling of a Composite Endpoint Using the Joint Modeling of Sparsely and Frequently Collected Subcomponents

  2020cites this paper
• Analysis of Longitudinal‐Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models

  2019cites this paper
• Model‐Based Comparison of Dose‐Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients

  2019cites this paper
• Research Techniques Made Simple: An Introduction to Drug Discovery for Dermatology.

  2019cites this paper
• Utility of Joint Population Exposure-Response Modeling Approach to Assess Multiple Continuous and Categorical Endpoints in Immunology Drug Development

  2019cites this paper
• Joint longitudinal model development: application to exposure–response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab

  2018cites this paper
• A comprehensive evaluation of exposure–response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis

  2018cites this paper
• Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure–response modeling of Mayo scores for golimumab in patients with ulcerative colitis

  2018cites this paper
• Exposure‐Response Modeling and Power Analysis of Components of ACR Response Criteria in Rheumatoid Arthritis (Part 1: Binary Model)

  2017cites this paper
• Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients

  2017cites this paper
• Exposure–Response Modeling and Power Analysis of Components of ACR Response Criteria in Rheumatoid Arthritis (Part 2: Continuous Model)

  2017cites this paper
• Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

  2017cites this paper
• Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

  2017cites this paper
• Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food

  2016cites this paper
• Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab

  2016cites this paper
• Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis

  2016cites this paper
• Erratum to: Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis

  2015cites this paper
• Pharmacometric Modeling in Rheumatoid Arthritis

  2015cites this paper
• Pharmacokinetic–pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)

  2015cites this paper
• Simultaneous Exposure–Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol

  2014cites this paper
• Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint

  2014cites this paper
• Exposure–Response Modeling of Clinical End Points Using Latent Variable Indirect Response Models

  2014cites this paper
• Pharmacometric Applications in Inflammation

  2014cites this paper
• Clinical endpoint sensitivity in rheumatoid arthritis: modeling and simulation

  2014cites this paper
• Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand–foot syndrome (HFS)

  2014cites this paper
• Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis

  2014cites this paper
• Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

  2013cites this paper
• Running title ( 56 / 60 characters including spaces ) : Preclinical to clinical translation of tofacitinib in RA

  2013cites this paper
• Tofacitinib

  2013cites this paper
• Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therapeutics

  2012cites this paper
• Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics

  2012cites this paper
• Latent variable indirect response modeling of categorical endpoints representing change from baseline

  2012influential citation
• Pharmacokinetic/pharmacodynamic modeling in inflammation.

  2012cites this paper
• Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.

  2012cites this paper
• Pharmacodynamic Models for Discrete Data

  2012cites this paper
• Estimating transformations for repeated measures modeling of continuous bounded outcome data

  2011cites this paper
• A case study of model‐based Bayesian dose response estimation

  2011cites this paper
• Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure–response modeling of physician’s global assessment score for ustekinumab in patients with psoriasis

  2011influential citation
• Extending the latent variable model for extra correlated longitudinal dichotomous responses

  2011cites this paper
• Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.

  2010cites this paper
• A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate

  2010influential citation
• Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.

  2010cites this paper
• A Pharmacodynamic Markov Mixed‐Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis

  2009cites this paper
• From pharmacokinetics to therapeutics

  2009cites this paper